Udenyca (pegfilgrastim-cbqv)

Manufacturer:

Coherus BioSciences

Route of Administration:

Subcutaneous

Site of Care:

Outpatient

Website:

Manufacturer Website

phone:

Enrollment Forms:

Synergen Prescription Form

Patient Support Form

Approved Indication:

to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of febrile neutropenia
to increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome)

Conditions:

Neutropenia Associated with Myelosuppressive Anti-Cancer Therapy
Hematopoietic Syndrome of Acute Radiation Syndrome

Therapeutic Area:

Oncology